Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status. / Rossing, Maria; Pedersen, Christina Bligaard; Tvedskov, Tove; Vejborg, Ilse; Talman, Maj Lis; Olsen, Lars Rønn; Kroman, Niels; Nielsen, Finn Cilius; Jensen, Maj Britt; Ejlertsen, Bent.
In: Scientific Reports, Vol. 11, No. 1, 2259, 12.2021.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Clinical implications of intrinsic molecular subtypes of breast cancer for sentinel node status
AU - Rossing, Maria
AU - Pedersen, Christina Bligaard
AU - Tvedskov, Tove
AU - Vejborg, Ilse
AU - Talman, Maj Lis
AU - Olsen, Lars Rønn
AU - Kroman, Niels
AU - Nielsen, Finn Cilius
AU - Jensen, Maj Britt
AU - Ejlertsen, Bent
N1 - Publisher Copyright: © 2021, The Author(s).
PY - 2021/12
Y1 - 2021/12
N2 - Axillary lymph node status is an important prognostic factor for breast cancer patients and sentinel lymph node biopsy (SLNB) is a less invasive surgical proxy. We examined if consecutively derived molecular subtypes from primary breast cancers provide additional predictive value for SLNB status. 1556 patients with a breast cancer > 10 mm underwent primary surgical procedure including SLNB and tumor specimens were assigned with a transcriptomics-based molecular subtype. 1020 patients had a negative sentinel node (SN) and 536 a positive. A significant association between tumor size and SN status (p < 0.0001) was found across all samples, but no association between size and SN status (p = 0.14) was found for BasL tumors. A BasL subtype was a predictor of an SN-negative status (p = 0.001, OR 0.58, 95% CI 0.38;0.90) and among the BasL, postmenopausal status was a predictor for SN-negative status (p = 0.01). Overall survival was significantly lower (p = 0.02) in patients with BasL tumors and a positive SN. Interestingly, we identified a significant correlation between hormone receptor activity and SN status within the BasL subtype. Taken together, molecular subtypes and hormone receptor activity of breast cancers add predictive value for SLNB status.
AB - Axillary lymph node status is an important prognostic factor for breast cancer patients and sentinel lymph node biopsy (SLNB) is a less invasive surgical proxy. We examined if consecutively derived molecular subtypes from primary breast cancers provide additional predictive value for SLNB status. 1556 patients with a breast cancer > 10 mm underwent primary surgical procedure including SLNB and tumor specimens were assigned with a transcriptomics-based molecular subtype. 1020 patients had a negative sentinel node (SN) and 536 a positive. A significant association between tumor size and SN status (p < 0.0001) was found across all samples, but no association between size and SN status (p = 0.14) was found for BasL tumors. A BasL subtype was a predictor of an SN-negative status (p = 0.001, OR 0.58, 95% CI 0.38;0.90) and among the BasL, postmenopausal status was a predictor for SN-negative status (p = 0.01). Overall survival was significantly lower (p = 0.02) in patients with BasL tumors and a positive SN. Interestingly, we identified a significant correlation between hormone receptor activity and SN status within the BasL subtype. Taken together, molecular subtypes and hormone receptor activity of breast cancers add predictive value for SLNB status.
U2 - 10.1038/s41598-021-81538-4
DO - 10.1038/s41598-021-81538-4
M3 - Journal article
C2 - 33500440
AN - SCOPUS:85099863583
VL - 11
JO - Scientific Reports
JF - Scientific Reports
SN - 2045-2322
IS - 1
M1 - 2259
ER -
ID: 278480102